Organon Acquired by Sun Pharma | Healthcare M&A Deal

Sun Pharma has acquired Organon, a pharmaceuticals business in the United States, for $11.75 billion. Sun Pharma acquisitions are aimed at strengthening healthcare M&A exposure by adding Organon’s branded medicines and specialty portfolio to its drug pipeline. Organon’s US operations in pharmaceuticals support Sun Pharma’s strategic acquisition plan to expand presence in key therapeutic areas and improve scale for future launches. The merger acquisition is classified as a strategic acquisition and is structured as Sun Pharma acquiring 100% of Organon’s outstanding equity at an enterprise value of $11.75 billion, with the deal announced and subject to customary closing conditions.